Inventiva reports its 2023 full-year results : comparemela.c

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and...

Related Keywords

Tianqing , Zhejiang , China , France , South Korea , Paris , France General , Russia , Ukraine , Israel , United States , Brussels , Bruxelles Capitale , Belgium , Milan , Lombardia , Italy , Daix , Bourgogne , New York , Cambridge , Cambridgeshire , United Kingdom , Japan , Chinese , French , Gilbert Dupont , Sino Biopharm , Julia Cailleteau , Pascaline Clerc , Aude Lepreux , Hepalys Pharma Inc , Nasdaq , Corporate Affairs , Data Monitoring Committee , Chia Tai Tianqing Pharmaceutical Group Co Ltd , Brunswick Group , Market Program , Patricial Bank , Exchange Commission , European Investment Bank On , Chinese National Medical Products Administration , University Of Florida , China National Medical Products Administration , European Investment Bank , Patient First Visit , Long Island City , Euronext Paris , Hepalys Pharma , Suspected Unexpected Serious Adverse Reaction , Investigational New Drug , At The Market Program , National Medical Products Administration , Breakthrough Therapy Designation , Kenneth Cusi , Metabolic Associated Fatty Liver Disease , Non Alcoholic Fatty Liver Disease , Phasei Renal Impairment , Access Event , European Healthcare Summit , Annual Conference Liver Connect , Nasdaq Global Market , Roquet Montegon , Private Securities Litigation Reform Act , New Drug Application , Universal Registration Document , Des March , Annual Report , Half Year Report , Year Results , Markets ,